Grifols Inkomsten in het verleden

Verleden criteriumcontroles 4/6

De winst van Grifols is gedaald met een gemiddeld jaarlijks percentage van -43.4%, terwijl de winst van de Biotechs -industrie jaarlijks groeide met 7.7%. De inkomsten zijn groeide met een gemiddeld percentage van 7% per jaar. Het rendement op het eigen vermogen Grifols bedraagt 2.8% en de nettomarge bedraagt 2.3%.

Belangrijke informatie

-43.4%

Groei van de winst

-35.0%

Groei van de winst per aandeel

Biotechs Groei van de industrie	-14.6%
Inkomstengroei	7.0%
Rendement op eigen vermogen	2.8%
Nettomarge	2.3%
Laatste winstupdate	30 Sep 2024

Recente prestatie-updates uit het verleden

Recent updates

Opbrengsten en kosten

Hoe Grifols geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.

Inkomsten en omzetgeschiedenis

DB:G0FB Opbrengsten, kosten en inkomsten (EUR Millions )
Datum	Inkomsten	Inkomsten	G+A Uitgaven	R&D-uitgaven
30 Sep 24	7,006	161	1,391	386
30 Jun 24	6,811	166	1,391	387
31 Mar 24	6,656	189	1,384	385
31 Dec 23	6,592	59	1,367	395
30 Sep 23	6,535	23	1,343	388
30 Jun 23	6,479	-5	1,217	388
31 Mar 23	6,358	47	1,345	390
31 Dec 22	6,064	208	1,190	361
30 Sep 22	5,549	149	1,138	353
30 Jun 22	5,207	66	1,122	358
31 Mar 22	5,016	112	1,064	359
31 Dec 21	4,933	189	1,062	355
30 Sep 21	5,044	361	1,046	337
30 Jun 21	5,199	667	1,008	311
31 Mar 21	5,231	562	992	298
31 Dec 20	5,340	619	986	294
30 Sep 20	5,392	687	971	288
30 Jun 20	5,353	557	976	286
31 Mar 20	5,235	697	959	281
31 Dec 19	5,099	625	943	276
30 Sep 19	4,961	552	923	271
30 Jun 19	4,790	565	878	261
31 Mar 19	4,620	568	859	249
31 Dec 18	4,487	597	815	241
30 Sep 18	4,332	699	777	212
30 Jun 18	4,246	704	804	215
31 Mar 18	4,279	672	800	219
31 Dec 17	4,318	663	860	225
30 Sep 17	4,348	571	857	230
30 Jun 17	4,291	559	827	222
31 Mar 17	4,153	554	810	209
31 Dec 16	4,050	545	775	198
30 Sep 16	4,014	537	771	216
30 Jun 16	3,986	535	776	218
31 Mar 16	3,985	529	768	221
31 Dec 15	3,935	532	736	224
30 Sep 15	3,789	533	696	211
30 Jun 15	3,645	507	686	199
31 Mar 15	3,466	478	666	194
31 Dec 14	3,355	470	661	181
30 Sep 14	3,133	417	647	161
30 Jun 14	2,972	388	614	150
31 Mar 14	2,856	376	584	132
31 Dec 13	2,742	346	558	123

Kwaliteitswinsten: G0FB heeft hoge kwaliteitsinkomsten.

Groeiende winstmarge: De huidige netto winstmarges (2.3%) G0FB } zijn hoger dan vorig jaar (0.4%).

Analyse vrije kasstroom versus winst

Analyse van de winstgroei in het verleden

Winsttrend: De winst van G0FB is de afgelopen 5 jaar met 43.4% per jaar gedaald.

Versnelling van de groei: De winstgroei van G0FB over het afgelopen jaar ( 590.4% ) overtreft het 5-jarig gemiddelde ( -43.4% per jaar).

Winst versus industrie: De winstgroei G0FB over het afgelopen jaar ( 590.4% ) overtrof de Biotechs -sector -20.8%.

Rendement op eigen vermogen

Hoge ROE: Het Rendement op eigen vermogen ( 2.8% ) van G0FB wordt als laag beschouwd.

Grifols Inkomsten in het verleden

Verleden criteriumcontroles 4/6

Belangrijke informatie

Recente prestatie-updates uit het verleden

Grifols, S.A. to Report Q2, 2024 Results on Jul 30, 2024

Grifols, S.A. to Report Q1, 2024 Results on May 14, 2024

Grifols, S.A. to Report Fiscal Year 2023 Results on Feb 29, 2024

Grifols, S.A. to Report Q3, 2023 Results on Nov 02, 2023

Grifols, S.A. to Report Fiscal Year 2022 Results on Feb 28, 2023

Grifols, S.A. to Report Q3, 2022 Results on Nov 08, 2022

Recent updates

Mason Capital Management Highlights Corporate Governance Failures and Significant Shareholder Value Destruction Under Grifols Board of Directors

Grifols Receives Fda Approval to Treat Surgical Bleeding in Pediatric Patients with Its Fibrin Sealant Solution

Brookfield Reportedly Courts Sovereign Funds to Join Grifols Takeover Bid

Grifols, S.A. Reaffirms Earnings Guidance for the Full Year 2024

Grifols Receives Expanded XEMBIFY (Immune Globulin Subcutaneous Human-Klhw) Label in U.S., Strengthening Its Ig Portfolio for Patients

Grifols Family Holders, Brookfield to Evaluate Possible Joint Takeover Bid

Haiyingkang (Qingdao) Medical Technology Co., Ltd. completed the acquisition of 20% equity stake in Shanghai RAAS Blood Products Co., Ltd. (SZSE:002252) from Grifols, S.A. (BME:GRF).

Grifols, S.A. to Report Q2, 2024 Results on Jul 30, 2024

Grifols, S.A., Annual General Meeting, Jun 13, 2024

Grifols, S.A. to Report Q1, 2024 Results on May 14, 2024

Grifols, S.A. Provides Earnings Guidance for the Year 2024

Grifols, S.A. Provides Earnings Guidance for the Year 2024

Grifols Announces Positive Topline Phase 3 Fibrinogen Clinical Trial Results

Grifols, S.A. Announces CEO Changes

Grifols, S.A. Announces Board Changes

Grifols, S.A. Announces Board Changes

Grifols, S.A. to Report Fiscal Year 2023 Results on Feb 29, 2024

Grifols Launches New Solution to Facilitate Pre-Transfusion Compatibility Testing in Multiple Myeloma Patients

Grifols Completes Cohort 1 in Clinical Study of Alpha-1 15%, Evaluating First-In-Human Subcutaneous Dosing Option for Patients with Alpha1-Antitrypsin Deficiency

Grifols Appoints Miguel Louzan as Chief Digital Information Officer

Grifols Achieves Positive Topline Results from Phase 4 Study of Xembify® (Immune Globulin Subcutaneous Human-Klhw) Evaluating Biweekly Dosing Option for Patients

Grifols Completes Enrollment in Phase 3 Study of Long-term Albutein® (albumin-human injection) Therapy for Patients with Decompensated Cirrhosis

Grifols Meets Enrollment Target in Phase 3 Study of Two Dose Regimens of Prolastin-C in Patients with Emphysema Due to Alpha-1-Antitrypsin Deficiency

Grifols Reportedly in Talks to Sell Raas Stake to China Resources

Grifols, S.A. to Report Q3, 2023 Results on Nov 02, 2023

Grifols, S.A., Annual General Meeting, Jun 15, 2023

Grifols Launches Alphaid™ At Home, Enabling U.S. Consumers to Self-Screen for Genetic Copd

Grifols, S.A. to Report Fiscal Year 2022 Results on Feb 28, 2023

Grifols, S.A. to Report Q3, 2022 Results on Nov 08, 2022

Grifols Receives FDA Clearance for AlphaID(TM) At Home, the First Free Service for U.S. Consumers to Determine Their Risk for Alpha-1

Grifols Announces Management Changes

Becton, Dickinson and Company (NYSE:BDX) acquired MedKeeper from Grifols, S.A. (BME:GRF) for $93 million.

Grifols, S.A. to Report First Half, 2022 Results on Jul 28, 2022

Grifols, S.A., Annual General Meeting, Jun 09, 2022

Grifols, S.A. (BME:GRF) completed the acquisition of a 45.48% stake in Biotest Aktiengesellschaft (XTRA : BIO3) from Tiancheng International Investment Limited.

Grifols, S.A. (BME:GRF) acquired Grifols Escrow Issuer, S.A.U. for $0.06 million.

Grifols to Provide Korean Red Cross with Procleix Panther for Blood Screening, Extending Donor Testing Leadership in Asia

Grifols, S.A. Declares Ordinary Dividend for the Fiscal Year Ended December 31, 2020, Payable on June 7, 2021

Grifols Takes Another Step in the Fight Against Alzheimer's, Partners with Ace to Open First Ambar® Center in Barcelona

Grifols Launches Patient Point-Of-Care System for Monitoring Infliximab in Europe

Grifols, S.A. (BME:GRF) acquired remaining 56% stake in GigaGen, Inc. for $80 million

Grifols, S.A. (BME:GRF) acquired 25 U.S. Based Plasma Donation Centers of BPL Plasma, Inc for $370 million.

Grifols, S.A.(BME:GRF.P) dropped from S&P Global BMI Index

Opbrengsten en kosten

Inkomsten en omzetgeschiedenis

Analyse vrije kasstroom versus winst

Analyse van de winstgroei in het verleden

Rendement op eigen vermogen

Rendement op activa

Rendement op geïnvesteerd vermogen

Ontdek sterk presterende bedrijven uit het verleden